drugset / Trial / NCT00329147

Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

NCT00329147

Phase 3 Completed 20 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.

Timeline

Start
2006-05
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Desipramine Small molecule
Subject Desvenlafaxine Other / unclassified
Subject Paroxetine Small molecule

Indications